LHLaura L. Hester

Laura L. Hester

*This is an algorithmically generated author record based on publicly available information.

Laura L. Hester has a total of 129 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Quantifying Preferences for CAR‐T Compared to Standard of Care as a First‐Line Treatment Among Patients With Multiple Myeloma

    by Jessie Sutphin, Thomas W. LeBlanc, Ellen Janssen, Laura Hester, Matthew J. Wallace, F. Reed Johnson, Shelby D. Reed

    Background: CAR‐T therapy is approved for the treatment of relapsed refractory multiple myeloma (MM) and is being studied for newly diagnosed MM (NDMM). The use of novel therapies in early‐line MM raises questions on the acceptability of upfront risks in exchange for extended relapse‐free periods without the treatment burden and limitations on daily activities associated with maintenance therapy.Methods: A discrete‐choice experiment was designed to elicit adults' preferences for hypothetical NDMM treatments. Benefits included time to relapse and reduction of treatment impact on daily activities. Severe adverse events were included to better understand patient preferences for rare but significant events.Results: On average, extending the time to relapse from 3 years (with moderate limitations on daily activities) to 5 years (without limitations) was three times more important than avoiding a 20% risk of hospitalization due to severe ICANS/CRS. Analysis revealed three latent preference classes: a benefit–risk trading class (65%), a class (28%) unwilling to accept increases in short‐term treatment‐related mortality, and a class (7%) that provided statistically uninformative data. For the trading class, for two additional relapse‐free years with minor limitations, all else equal, patients would accept up to a 30% risk of severe ICANS/CRS‐related hospitalization along with 0% risk of treatment‐related mortality. Alternatively, they would accept up to an 8% risk of treatment‐related mortality with a 0% risk of severe ICANS/CRS‐related hospitalization, or various combinations of lower AE risks.Conclusion: These results reveal preference heterogeneity among MM patients and the importance of effective communication about the benefits and risks of novel therapies.


  • Top Cited Papers
    Open Access

    Real-World Safety and Health Care Resource Utilization of Teclistamab Under an Outpatient Model for Step-Up Dosing Administration

    by Tyler B. Sandahl, Scott A. Soefje, Rafael Fonseca, Sikander Ailawadhi, Ricardo Parrondo, Dee Lin, Bingcao Wu, Ediz S. Calay, Eli Silvert, Nina Kim, et al.

    PURPOSE: Teclistamab is initiated with a step-up dosing (SUD) schedule to mitigate the risk of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS). Early teclistamab users commonly received SUD in a hospital setting. This study aimed to evaluate safety and health care resource utilization (HRU) in real-world patients with multiple myeloma who initiated teclistamab SUD in an outpatient setting. METHODS: This was a retrospective study using Mayo Clinic's electronic medical records from October 26, 2022, to October 31, 2023. Patient characteristics were summarized for all patients treated with teclistamab and separately for patients who started SUD outpatient. SUD pattern, safety, HRU, and post-SUD dosing schedule were described in patients with complete SUD. RESULTS: At data cutoff, 65 patients received ≥1 teclistamab dose, including 58 patients who initiated SUD outpatient (median age, 69.2 years; male, 63.8%; White, 89.7%). Among 57 patients who completed SUD in an outpatient setting, all received premedications on the days of teclistamab administrations per label recommendation; 18 (31.6%) developed CRS (13 grade 1, four grade 2, and one grade 4) and two developed ICANS (one each with grade 2 and 4). All CRS and ICANS resolved with supportive care and all patients continued treatment. Eighteen patients were admitted to the hospital for CRS treatment, with a median CRS-related hospital stay of 2 days per admission. Most (60%) doses during SUD required <1 hour clinic time between administration and checkout. Post-SUD, clinic time for treatment doses decreased to <30 minutes for most doses (82%). CONCLUSION: Outcomes of this study support outpatient administration as a safe and feasible option for teclistamab SUD to potentially reduce HRU and improve patient experiences.


  • Epidemiology and clinical outcomes of light‐chain amyloidosis in Sweden: A nationwide population‐based study

    by Ulf‐Henrik Mellqvist, Qian Cai, Laura L. Hester, Michael Grövdal, Jakob Börsum, Iffat Rahman, Eric M. Ammann, Markus Hansson

    Objectives: This study evaluated data from six Swedish national registries to fill current evidence gaps on the epidemiology, clinical burden, and overall survival (OS) associated with light‐chain (AL) amyloidosis.Methods: Patients newly diagnosed with AL amyloidosis were identified using six linked Swedish nationwide population‐based registers. For each case, individuals from the general population were selected and matched with a maximum ratio of 1:5 based on age, sex, calendar year, and county.Results: 846 patients newly diagnosed with AL amyloidosis and 4227 demographically matched individuals were identified. From 2011 to 2019, annual AL amyloidosis incidence increased from 10.5 to 15.1 cases per million. At baseline, patients with AL amyloidosis had a significantly higher disease burden including higher rates of cardiac and renal failure relative to the comparison group. Among patients with AL amyloidosis, 21.5% had incident heart failure and 17.1% had incident renal failure after initial diagnosis. Median OS for patients with AL amyloidosis was 56 months versus not reached in the matched general population comparison group.Conclusion: The incidence of newly diagnosed AL amyloidosis in Sweden increased over time with AL amyloidosis being associated with a higher risk of cardiac/renal failure and all‐cause mortality compared with the general population.


  • Open Access

    Identifying signs and symptoms of AL amyloidosis in electronic health records using natural language processing, diagnosis codes, and manually abstracted registry data

    by Eli Silvert, Laura Hester, Eshwan Ramudu, Colin Pawlowski, Britte Kranenburg, Francis Buadi, Eli Muchtar, Samer Khaled, Namphuong Tran, Venky Soundararajan, et al.


  • Open Access

    Update on prevalence of diagnosed systemic lupus erythematosus (SLE) by major health insurance types in the US in 2016

    by Yiting Wang, Laura L. Hester, Jennifer Lofland, Shawn Rose, Chetan S. Karyekar, David M. Kern, Margaret Blacketer, Kourtney Davis, Kimberly Shields-Tuttle

    Objective: To provide current estimates of the number of patients with prevalent systemic lupus erythematosus (SLE) by major health insurance types in the US and to describe patient characteristics. Four large US health insurance claims databases were analyzed to represent different types of insurance coverage, including private insurance, Medicaid, and Medicare Supplemental. Results: Overall unadjusted SLE prevalence per 100,000 persons in the US ranged from 150.1 (private insurance) to 252.9 (Medicare Supplemental insurance). Extrapolating to the US civilian population in 2016, we estimated roughly 345,000 to 404,000 prevalent SLE patients with private/Medicare insurance and 99,000 prevalent SLE patients with Medicaid insurance. Comorbidities, including renal failure/dialysis were commonly observed across multiple organ systems in SLE patients (8.4–21.1%). We estimated a larger number of prevalent SLE cases in the US civilian population than previous reports and observed extensive disease burden based on a 1-year cross-sectional analysis.


  • Open Access

    Characteristics and Outcomes of Over 300,000 Patients with COVID-19 and History of Cancer in the United States and Spain

    by Elena Roel, Andrea Pistillo, Martina Recalde, Anthony G. Sena, Sergio Fernández-Bertolín, Maria Aragón, Diana Puente, Waheed-Ul-Rahman Ahmed, Heba Alghoul, Osaid Alser, et al.

    Background: We described the demographics, cancer subtypes, comorbidities, and outcomes of patients with a history of cancer and coronavirus disease 2019 (COVID-19). Second, we compared patients hospitalized with COVID-19 to patients diagnosed with COVID-19 and patients hospitalized with influenza. Methods: We conducted a cohort study using eight routinely collected health care databases from Spain and the United States, standardized to the Observational Medical Outcome Partnership common data model. Three cohorts of patients with a history of cancer were included: (i) diagnosed with COVID-19, (ii) hospitalized with COVID-19, and (iii) hospitalized with influenza in 2017 to 2018. Patients were followed from index date to 30 days or death. We reported demographics, cancer subtypes, comorbidities, and 30-day outcomes. Results: We included 366,050 and 119,597 patients diagnosed and hospitalized with COVID-19, respectively. Prostate and breast cancers were the most frequent cancers (range: 5%–18% and 1%–14% in the diagnosed cohort, respectively). Hematologic malignancies were also frequent, with non-Hodgkin's lymphoma being among the five most common cancer subtypes in the diagnosed cohort. Overall, patients were aged above 65 years and had multiple comorbidities. Occurrence of death ranged from 2% to 14% and from 6% to 26% in the diagnosed and hospitalized COVID-19 cohorts, respectively. Patients hospitalized with influenza (n = 67,743) had a similar distribution of cancer subtypes, sex, age, and comorbidities but lower occurrence of adverse events. Conclusions: Patients with a history of cancer and COVID-19 had multiple comorbidities and a high occurrence of COVID-19-related events. Hematologic malignancies were frequent. Impact: This study provides epidemiologic characteristics that can inform clinical care and etiologic studies.


  • Diagnostic delay and characterization of the clinical prodrome in AL amyloidosis among 1523 US adults diagnosed between 2001 and 2019

    by Laura L. Hester, Dina M. Gifkins, Kevin M. Bellew, Jessica Vermeulen, Jordan M. Schecter, John Strony, Victor Dishy, Brendan M. Weiss

    Light‐chain (AL) amyloidosis is a multisystem disorder with a high early mortality and diagnostic delays of >1 year from symptom onset. This retrospective observational study sought to characterize the clinical prodrome and diagnostic delay to inform early detection. We identified 1523 adults with newly diagnosed AL amyloidosis in the Optum de‐identified Clinformatics® Datamart US healthcare claims database as those with ≥2 new diagnosis codes for AL or other amyloidosis in 90 days with ≥1 multiple myeloma treatment within 730 days, excluding patients with prior hereditary or secondary amyloidosis and Familial Mediterranean Fever. We considered 34 signs/symptoms using diagnosis codes in all observable time on or before AL amyloidosis diagnosis. Sign/symptom prevalence was compared to that of 1:4 matched population controls. The overlap and sequence of signs/symptoms and the median time from first sign/symptom to AL amyloidosis diagnosis were explored. Healthcare utilization was summarized. The most common individual AL amyloidosis signs/symptoms were malaise/fatigue (61%) and dyspnea (59%). Cardiac signs/symptoms were observed in 77% of patients, followed by renal (62%) and neurologic (59%) signs/symptoms. Multisystem involvement (≥3 systems) was present in 54%. Monoclonal gammopathy was detected in 29% before diagnosis. Median time from symptom onset to AL amyloidosis diagnosis was 2.7 years. Healthcare utilization was high between first AL amyloidosis signs/symptoms and diagnosis, with 50% visiting ≥5 physician types. AL amyloidosis patients have a lengthy and complex clinical prodrome. Novel approaches to early diagnosis are needed to improve outcomes.


  • Open Access

    Diagnostic Delay and Characterization of the Clinical Prodrome in AL Amyloidosis: Data from 1,313 US Commercially Insured Patients between 2006-2018

    by Laura L Hester, Dina M Gifkins, Kevin M Bellew, Jessica Vermeulen, Jordan M Schecter, Frank J DeFalco, Brendan M Weiss

    Introduction:Light chain (AL) amyloidosis is a rare clonal plasma cell disorder characterized by the organ deposition of amyloid derived from misfolded immunoglobulin light chains. The involvement of vital organs, especially the heart, results in severe morbidity and high early mortality. Diagnostic delays of greater than 1 year from clinical evidence of AL have been reported in surveys and retrospective single-center studies. Earlier diagnosis prior to developing advanced organ dysfunction is a key unmet need in AL. To detect patients earlier, a better understanding of the patterns of AL-related signs/symptoms (AL-S/Sx) and healthcare utilization preceding AL amyloidosis diagnosis is necessary. Methods: Using the Optum De-Identified Clinformatics® Data Mart healthcare claims database (Optum), we identified US commercially-insured patients who had one inpatient code or two outpatient codes of ICD-9-CM 277.30 or ICD-10-CM E85.81, E85.89, or E85.9 and treatment with one multiple myeloma drug within 90 days of diagnosis (01Jan06-31Dec18). Twenty-three AL-S/Sx were defined with sets of diagnosis codes, flagged in prior condition lists, and grouped by system affected (cardiac, nervous, renal/ureter, gastrointestinal, or other). The time between the first occurrence of each symptom and AL diagnosis was summarized and healthcare utilization patterns were described to better characterize the patient journey to diagnosis. Results: Among 1313 AL patients, the median time from the first potential AL-S/Sx to AL diagnosis was 2.5 years. The most common AL-S/Sx were malaise/fatigue (53%), edema and swelling (57%), dyspnea (53%), and abdominal pain (52%), which occurred a median of 1-1.8 years prior to diagnosis. Arrhythmia (51%), cardiomegaly (27%), and cardiomyopathy (21%) were identifiable between a median of 1-1.5 years before diagnosis. Chronic kidney disease (45%) and edema (57%) were seen a median of 2.3 years prior to diagnosis. Patients with a first symptom of nephrotic syndrome presented less than 1 year before diagnosis. Peripheral nerve disease (46%), neuralgias (14%), and paresthesia/anesthesia (20%) appeared a median of 2.8 years prior to diagnosis. The cumulative incidence of each AL-S/Sx by organ system in the 5 years prior to diagnosis is shown in Figure 1. Sequencing of symptoms varied greatly among patients. The most common first symptoms in the sequences were abdominal pain, malaise/fatigue/weakness, peripheral nerve disease, and arrhythmia. Between initial AL-S/Sx and diagnosis, 20% of patients had 3 or more ER visits and 16% had 3 or more hospitalizations. More than 90% of patients visited 5 or more provider types between the first AL-S/Sx and AL diagnosis, with the most frequent specialties visited being cardiology (67%), hematology/oncology (43%), and gastroenterology (40%). About one quarter of patients had a monoclonal gammopathy detected at a median of 1 year prior to diagnosis; detailed analyses of this cohort will be presented at the meeting. Conclusion: AL patients have a prolonged prodrome, including evidence of cardiac and renal dysfunction, with 50% of patients with a first AL-S/Sx observed more than 2.5 years before AL diagnosis. Only one-quarter of patients had a monoclonal protein detected before diagnosis, indicating a low level of suspicion for AL. Limitations of this study include underestimation of AL S/Sx if diagnosis codes are underutilized in claims. Future studies will use controls to understand background rates of symptoms. Overall, these findings suggest that novel approaches to early diagnosis have significant potential to improve outcomes in AL. Figure 1.Cumulative incidence of the first occurrence of potential symptoms prior to the first light chain (AL) amyloidosis diagnosis


  • Comparison of Medicare Claims-based Proxy Measures of Poor Function and Associations With Treatment Receipt and Mortality in Older Colon Cancer Patients

    by Sophie E. Mayer, Hung-Jui Md Tan, Sharon Mpa Peacock Hinton, Hanna K. Sanoff, Til Stürmer, Laura L. PhD Hester, Keturah R. Faurot, Michele Jonsson Funk, Jennifer L. Lund

    Background: Multiple claims-based proxy measures of poor function have been developed to address confounding in observational studies of drug effects in older adults. We evaluated agreement between these measures and their associations with treatment receipt and mortality in a cohort of older colon cancer patients. Methods: Medicare beneficiaries age 66+ diagnosed with stage II–III colon cancer were identified in the Surveillance, Epidemiology, and End Results-Medicare database (2004–2011). Poor function was operationalized by: (1) summing the total poor function indicators for each model; and (2) estimating predicted probabilities of poor function at diagnosis. Agreement was evaluated using Fleiss’ κ and Spearman’s correlation. Associations between proxy measures and: (1) laparoscopic versus open surgery; (2) chemotherapy versus none; (3) 5-fluorouracil (5FU)+oxaliplatin (FOLFOX) versus 5FU monotherapy; and (4) 1-year mortality were estimated using log-binomial regression, controlling for age, sex, stage, and comorbidity. Survival estimates were stratified by functional group, age, and comorbidity. Results: Among 29,687 eligible colon cancer patients, 67% were 75+ years and 45% had stage III disease. Concordance across the poor function indicator counts was moderate (κ: 0.64) and correlation of predicted probability measures varied (ρ: 0.21–0.74). Worse function was associated with lower chemotherapy and FOLFOX receipt, and higher 1-year mortality. Within age and comorbidity strata, poor function remained associated with mortality. Conclusions: While agreement varied across the claims-based proxy measures, each demonstrated anticipated associations with treatment receipt and mortality independent of comorbidity. Claims-based comparative effectiveness studies in older populations should consider applying one of these models to improve confounding control.


  • Cause‐specific mortality among Medicare beneficiaries with newly diagnosed non‐Hodgkin lymphoma subtypes

    by Laura L. Hester, Steven I. Park, William A. Wood, Til Stürmer, M. Alan Brookhart, Jennifer L. Lund

    Background: As the US population ages and non‐Hodgkin lymphoma (NHL)–specific mortality declines, deaths from causes other than NHL will become increasingly important in treatment decision making for older patients with NHL. The objective of the current study was to describe how the 5‐year cumulative incidence of NHL‐specific and other‐cause mortality varies by subtype, age, comorbidity level, and time since diagnosis in older patients. Methods: Using the Surveillance, Epidemiology, and End Results cancer registry data linked to Medicare claims, patients aged ≥66 years were identified at the time of diagnosis with a first, primary NHL diagnosis from 2004 through 2013. Death certificate data and Fine‐Gray competing risks models were used to estimate the 5‐year cumulative incidence of NHL‐specific and other‐cause mortality by NHL subtype, age, and comorbidity level. Estimates were displayed over time using stacked cumulative incidence curves. Results: Among 30,666 patients with NHL, 32% died of NHL and 13% died of other causes within 5 years of diagnosis. The cumulative incidence of other‐cause mortality increased with age and comorbidity level for all subtypes. Among patients with aggressive NHL subtypes, NHL‐specific mortality exceeded other‐cause mortality across all age groups, comorbidity levels, and number of years after diagnosis. For patients with indolent NHL subtypes, other‐cause mortality was similar to or exceeded NHL‐specific mortality, especially among older patients with severe comorbidity or with the indolent marginal zone, lymphoplasmacytic, and mycosis fungoides subtypes. Conclusions: The findings of the current study suggest that mortality from causes other than NHL are important for patients of an older age, with a higher comorbidity level, and with indolent disease. Evidence from the current study can guide the development of tools for estimating individual prognosis that inform treatment discussions in patients with NHL.